This study is in progress, not accepting new patients

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

a study on Malignancies Non-Small Cell Lung Cancer Ovarian Cancer Transitional Cell Carcinoma Solid Tumor

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Deborah Wong (ucla)

Description

Summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Official Title

Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.

Details

B9991046 is a master protocol that will consist of sub-studies from the following parent studies:

B9991001 - NCT02603432 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058 B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991

Keywords

Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors, BRCA Mutant Tumors, ATM Mutant Tumors, Pemetrexed, Avelumab, Axitinib, Talazoparib, Lorlatanib, CMP 001, Utomilumab

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study.
  2. Participants must agree to follow the reproductive criteria.
  3. Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.

You CAN'T join if...

  1. Female participants who are pregnant or breastfeeding.
  2. Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.

Locations

  • UCLA Hematology/Oncology - Administrative Office
    Los Angeles California 90024 United States
  • Ronald Reagan UCLA Medical Center - Drug Information Center, Pharmaceutical Services
    Los Angeles California 90095 United States
  • UCLA Hematology/Oncology
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
Links
To obtain contact information for a study center near you, click here.
ID
NCT05059522
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 67 people participating
Last Updated